Filtered By:
Therapy: Cancer Therapy

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 4168 results found since Jan 2013.

Current Status of PSMA-Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization
Nucl Med Mol Imaging. 2022 Dec;56(6):263-281. doi: 10.1007/s13139-022-00764-4. Epub 2022 Aug 20.ABSTRACTProstate-specific membrane antigen (PSMA) is highly expressed in PCa, which gradually increases in high-grade tumors, metastatic tumors, and tumors nonresponsive to androgen deprivation therapy. PSMA has been a topic of interest during the past decade for both diagnostic and therapeutic targets. Radioligand therapy (RLT) utilizes the delivery of radioactive nuclides to tumors and tumor-associated targets, and it has shown better efficacy with minimal toxicity compared to other systemic cancer therapies. Nuclear medicine ...
Source: Molecular Medicine - November 25, 2022 Category: Molecular Biology Authors: So Won Oh Minseok Suh Gi Jeong Cheon Source Type: research

Correction to: Nuclear medicine in the assessment and prevention of cancer therapy ‑related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM)
Source: European Journal of Nuclear Medicine and Molecular Imaging - January 19, 2023 Category: Nuclear Medicine Source Type: research

Molecular biomarkers for facilitating genome ‑directed precision medicine in gynecological cancer (Review)
Oncol Lett. 2023 Aug 17;26(4):426. doi: 10.3892/ol.2023.14012. eCollection 2023 Oct.ABSTRACTProminent recent advancements in cancer treatment include the development and clinical application of next-generation sequencing (NGS) technologies, alongside a diverse array of novel molecular targeting therapeutics. NGS has enabled the high-speed and low-cost sequencing of whole genomes in individual patients, which has opened the era of genome-based precision medicine. The development of numerous molecular targeting agents, including anti-VEGF antibodies, poly (ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors, h...
Source: Oncology Letters - September 4, 2023 Category: Cancer & Oncology Authors: Takeo Minaguchi Ayumi Shikama Azusa Akiyama Toyomi Satoh Source Type: research

Murraya koenigii leaf extract inhibits proteasome activity and induces cell death in breast cancer cells
Conclusions: Our study suggests M. koenigii leaves to be a potent source of proteasome inhibitors that lead to cancer cell death. Therefore, identification of active component(s) from the leaf extract could lead to the development of anti-cancer agents which could be useful in the treatment of different types of cancers.
Source: BMC Complementary and Alternative Medicine - January 9, 2013 Category: Complementary Medicine Authors: Bindu NooluRajanna AjumeeraAnitha ChauhanBalakrishna NagallaRaghunath ManchalaAyesha Ismail Source Type: research

Development of a miR‐92a delivery system for anti‐angiogenesis‐based cancer therapy
ConclusionsWe have developed a miR‐92a delivery system into angiogenic endothelial cells by the use of TEPA‐PCL. These results suggest that miR‐92a‐C/TEPA‐PCL is promising for the treatment of tumors via the suppression of angiogenesis. Copyright © 2012 John Wiley & Sons, Ltd.
Source: The Journal of Gene Medicine - January 25, 2013 Category: Genetics & Stem Cells Authors: Hidenori Ando, Ayaka Okamoto, Masafumi Yokota, Kosuke Shimizu, Tomohiro Asai, Takehisa Dewa, Naoto Oku Tags: Research Article Source Type: research

BUSM authors propose potential epigenetic mechanisms for improved cancer therapy
(Boston University Medical Center) A review article by researchers at Boston University School of Medicine proposes a new epigenetic hypothesis linked to tumor production and novel ideas about what causes progenitor cells to develop into cancer cells.
Source: EurekAlert! - Medicine and Health - February 19, 2013 Category: Global & Universal Source Type: news

The future of personalized and targeted cancer therapy
(University of Pennsylvania School of Medicine) A panel discussion at the AACR Annual Meeting 2013 -- featuring the University of Pennsylvania physician-scientist leading the research team whose work has spurred worldwide attention to chimeric antigen receptor technologies, and a trial participant whose leukemia remains in remission more than two and a half years after being treated with his own engineered cells -- will explore the future of personalized cellular therapies.
Source: EurekAlert! - Medicine and Health - April 5, 2013 Category: Global & Universal Source Type: news

Investigating the Perceived Feasibility of Integrative Medicine in a Conventional Oncology Setting: Yoga Therapy as a Treatment for Breast Cancer Survivors
Conclusions. Although enthusiasm for the implementation of an integrative yoga therapy program was apparent among both breast cancer survivors and HCPs, barriers were also identified. The findings of this study are currently being used to inform a large-scale program of research aimed at developing integrative treatment services for breast cancer patients, beginning with yoga therapy.
Source: Integrative Cancer Therapies - March 4, 2013 Category: Cancer & Oncology Authors: Slocum-Gori, S., Howard, A. F., Balneaves, L. G., Kazanjian, A. Tags: Articles Source Type: research

Cancer therapy: A Notch further with SERCA
Nature Medicine 19, 546 (2013). doi:10.1038/nm.3208 Author: Benjamin Boettner
Source: Nature Medicine - May 7, 2013 Category: Journals (General) Authors: Benjamin Boettner Tags: Research Highlights Source Type: research

Keeping the balance--an overview of mind-body therapies in pediatric oncology.
Abstract This overview aims to give a brief introduction for clinicians in the wide field of Mind-Body Therapies (MBTs), to summarize the current research status of MBTs in pediatric oncology and to mention challenges for future goals. Most used techniques (relaxation, hypnosis, yoga, massage, MBSR, eurythmy) will be described and efficacy will be discussed. MBTs are an enhancement of conventional medicine to motivate the patient to participate in his recovery. Most MBTs are of low risk and are accessible for patients and their families in nearly all stadium of cancer therapy. Positive results include increased se...
Source: Complementary Therapies in Medicine - April 1, 2013 Category: Complementary Medicine Authors: Kanitz JL, Camus ME, Seifert G Tags: Complement Ther Med Source Type: research

UNC scientists identify possible KRAS downstream target for pancreatic cancer therapy
(University of North Carolina Health Care) A University of North Carolina School of Medicine team offers first evidence of the role of a protein called GSK-3 alpha in promoting oncogenic KRAS function.
Source: EurekAlert! - Medicine and Health - May 28, 2013 Category: Global & Universal Source Type: news